Cover Image
市場調查報告書

大腸癌 : 開發中產品分析

Colon Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229732
出版日期 內容資訊 英文 745 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌 : 開發中產品分析 Colon Cancer - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 745 Pages
簡介

大腸・結腸直腸癌是指在大腸(結腸)或直腸發病的癌症。並沒有特定的單一原因。幾乎所有的大腸癌都是從非癌性(良性)息肉開始慢慢發展成癌症。許多情況下並沒有症狀。常見的症狀有腹痛和下腹部的壓痛、血便、腹瀉、便秘、或排便習慣的變化、原因不明的體重減少等。治療方法包含外科手術,放射線治療,化療等。

本報告提供大腸癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

大腸癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9471IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H1 2017, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 12, 35, 4, 168 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 44 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Colon Cancer - Overview
  • Colon Cancer - Therapeutics Development
  • Colon Cancer - Therapeutics Assessment
  • Colon Cancer - Companies Involved in Therapeutics Development
  • Colon Cancer - Drug Profiles
  • Colon Cancer - Dormant Projects
  • Colon Cancer - Discontinued Products
  • Colon Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Colon Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Colon Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
  • Colon Cancer - Pipeline by 4P-Pharma SAS, H1 2017
  • Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Adamed Sp z oo, H1 2017
  • Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2017
  • Colon Cancer - Pipeline by Aduro BioTech Inc, H1 2017
  • Colon Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
  • Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H1 2017
  • Colon Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Affimed GmbH, H1 2017
  • Colon Cancer - Pipeline by Agenus Inc, H1 2017
  • Colon Cancer - Pipeline by AGV Discovery SAS, H1 2017
  • Colon Cancer - Pipeline by AIMM Therapeutics BV, H1 2017
  • Colon Cancer - Pipeline by Ambrx Inc, H1 2017
  • Colon Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Colon Cancer - Pipeline by AndroScience Corp, H1 2017
  • Colon Cancer - Pipeline by ANP Technologies Inc, H1 2017
  • Colon Cancer - Pipeline by Aphios Corp, H1 2017
  • Colon Cancer - Pipeline by Aposense Ltd, H1 2017
  • Colon Cancer - Pipeline by Aptose Biosciences Inc, H1 2017
  • Colon Cancer - Pipeline by Asana BioSciences LLC, H1 2017
  • Colon Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Colon Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Colon Cancer - Pipeline by Bayer AG, H1 2017
  • Colon Cancer - Pipeline by BCN Biosciences LLC, H1 2017
  • Colon Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by BioCancell Ltd, H1 2017
  • Colon Cancer - Pipeline by Biogazelle NV, H1 2017
  • Colon Cancer - Pipeline by Blirt SA, H1 2017
  • Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Colon Cancer - Pipeline by Celgene Corp, H1 2017
  • Colon Cancer - Pipeline by Celprogen Inc, H1 2017
  • Colon Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Colon Cancer - Pipeline by CrystalGenomics Inc, H1 2017
  • Colon Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Cytune Pharma SAS, H1 2017
  • Colon Cancer - Pipeline by CZ BioMed Corp, H1 2017
  • Colon Cancer - Pipeline by Debiopharm International SA, H1 2017
  • Colon Cancer - Pipeline by DEKK-TEC Inc, H1 2017
  • Colon Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Colon Cancer - Pipeline by EntreChem SL, H1 2017
  • Colon Cancer - Pipeline by EnzymeBioSystems, H1 2017
  • Colon Cancer - Pipeline by F-star Biotechnology Ltd, H1 2017
  • Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Colon Cancer - Pipeline by G1 Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Colon Cancer - Pipeline by GlycaNova Norway AS, H1 2017
  • Colon Cancer - Pipeline by GlycoMimetics Inc, H1 2017
  • Colon Cancer - Pipeline by Griffith University, H1 2017
  • Colon Cancer - Pipeline by Grunenthal GmbH, H1 2017
  • Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Hamlet Pharma AB, H1 2017
  • Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Colon Cancer - Pipeline by Histogen Inc, H1 2017
  • Colon Cancer - Pipeline by HitGen LTD, H1 2017
  • Colon Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Colon Cancer - Pipeline by Hummingbird Bioscience Pte Ltd, H1 2017
  • Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Colon Cancer - Pipeline by Immunotope Inc, H1 2017
  • Colon Cancer - Pipeline by Immupharma Plc, H1 2017
  • Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Innopharmax Inc, H1 2017
  • Colon Cancer - Pipeline by Intezyne Technologies Inc, H1 2017
  • Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H1 2017
  • Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
  • Colon Cancer - Pipeline by JW Pharmaceutical Corp, H1 2017
  • Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Kineta Inc, H1 2017
  • Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Colon Cancer - Pipeline by Lipocure Ltd, H1 2017
  • Colon Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Colon Cancer - Pipeline by Loxo Oncology Inc, H1 2017
  • Colon Cancer - Pipeline by Lupin Ltd, H1 2017
  • Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H1 2017
  • Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
  • Colon Cancer - Pipeline by MacroGenics Inc, H1 2017
  • Colon Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by MaxiVAX SA, H1 2017
  • Colon Cancer - Pipeline by Meabco A/S, H1 2017
  • Colon Cancer - Pipeline by Medicenna Therapeutics Corp, H1 2017
  • Colon Cancer - Pipeline by Merus NV, H1 2017
  • Colon Cancer - Pipeline by Microlin Bio Inc, H1 2017
  • Colon Cancer - Pipeline by Moderna Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H1 2017
  • Colon Cancer - Pipeline by MolMed SpA, H1 2017
  • Colon Cancer - Pipeline by Mologen AG, H1 2017
  • Colon Cancer - Pipeline by Monopar Therapeutics LLC, H1 2017
  • Colon Cancer - Pipeline by Multimmune GmbH, H1 2017
  • Colon Cancer - Pipeline by Nektar Therapeutics, H1 2017
  • Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Novartis AG, H1 2017
  • Colon Cancer - Pipeline by Omeros Corp, H1 2017
  • Colon Cancer - Pipeline by OncoResponse Inc, H1 2017
  • Colon Cancer - Pipeline by Oncovir Inc, H1 2017
  • Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Colon Cancer - Pipeline by Orega Biotech SAS, H1 2017
  • Colon Cancer - Pipeline by OSE Immunotherapeutics, H1 2017
  • Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Patrys Ltd, H1 2017
  • Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H1 2017
  • Colon Cancer - Pipeline by Pharminox Ltd, H1 2017
  • Colon Cancer - Pipeline by Philogen SpA, H1 2017
  • Colon Cancer - Pipeline by Plexxikon Inc, H1 2017
  • Colon Cancer - Pipeline by Provecs Medical GmbH, H1 2017
  • Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Qu Biologics Inc, H1 2017
  • Colon Cancer - Pipeline by Redx Pharma Plc, H1 2017
  • Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Rgenix Inc, H1 2017
  • Colon Cancer - Pipeline by Sareum Holdings Plc, H1 2017
  • Colon Cancer - Pipeline by Sierra Oncology Inc, H1 2017
  • Colon Cancer - Pipeline by Sigma-Tau SpA, H1 2017
  • Colon Cancer - Pipeline by Sirnaomics Inc, H1 2017
  • Colon Cancer - Pipeline by Somantix BV, H1 2017
  • Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
  • Colon Cancer - Pipeline by Starpharma Holdings Ltd, H1 2017
  • Colon Cancer - Pipeline by Sunshine Biopharma Inc, H1 2017
  • Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H1 2017
  • Colon Cancer - Pipeline by Systimmune Inc, H1 2017
  • Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Colon Cancer - Pipeline by Takis Srl, H1 2017
  • Colon Cancer - Pipeline by Transgene Biotek Ltd, H1 2017
  • Colon Cancer - Pipeline by TVAX Biomedical Inc, H1 2017
  • Colon Cancer - Pipeline by Tyg Oncology Ltd, H1 2017
  • Colon Cancer - Pipeline by Vaccibody AS, H1 2017
  • Colon Cancer - Pipeline by Vaccinogen Inc, H1 2017
  • Colon Cancer - Pipeline by Vault Pharma Inc, H1 2017
  • Colon Cancer - Pipeline by Vaxenta Biotechnologies, H1 2017
  • Colon Cancer - Pipeline by Vernalis Plc, H1 2017
  • Colon Cancer - Pipeline by VG Life Sciences Inc, H1 2017
  • Colon Cancer - Pipeline by Vivolux AB, H1 2017
  • Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H1 2017
  • Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • Colon Cancer - Dormant Projects, H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Colon Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Colon Cancer - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Colon Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top